Biomics Biopharma (ASX:BBM) Cash-to-Debt : 0.00 (As of . 20)

Biomics Biopharma Cash-to-Debt Chart

Competitive Comparison of Biomics Biopharma's Cash-to-Debt

For the Biotechnology subindustry, Biomics Biopharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomics Biopharma's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomics Biopharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Biomics Biopharma's Cash-to-Debt falls into.

Biomics Biopharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Biomics Biopharma's Cash to Debt Ratio for the fiscal year that ended in . 20 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

Biomics Biopharma's Cash to Debt Ratio for the quarter that ended in . 20 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomics Biopharma  (ASX:BBM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Biomics Biopharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Biomics Biopharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomics Biopharma (ASX:BBM) Business Description